Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
332 total articles
F.N.B. Corp. is trading like a plain-vanilla regional bank, but the business mix (banking plus wealth and insurance) and its footprint across seven states and D.C. give it more ways to win as the rate cycle evolves. With shares near $17.39, FNB sits below its recent $18.30 high while valued at roughly 0.92x book and about 11-12x earnings. This trad…
Roche’s CT-388 obesity data is good enough to matter and, more importantly, good enough to keep investors paying attention as Phase 3 ramps. But the stock is pressing fresh 52-week highs with an overbought RSI, which makes the risk-reward poor if you chase. The trade: wait for a pullback toward moving-average support, then look for a swing entry wi…
Zeta Global sits at the intersection of two durable trends: AI-assisted marketing automation and first-party consumer intelligence. The stock has pulled back to ~$20 despite recent upbeat coverage and a prior earnings-driven surge, while liquidity and leverage metrics look reasonable for a growth software name. With ZETA trading below short-term mo…
Allstate looks past the headline “turnaround” phase and into a steadier compounding setup: strong profitability metrics, substantial free cash flow, and a single-digit earnings multiple while the stock sits below key moving averages with a depressed RSI. I like a mid-term long with a tight invalidation level and a defined upside target as sentiment…
Oceaneering is breaking out to fresh 52-week highs on strong momentum and heavy volume. The bull case is that OII sits in a hard-to-replace niche: subsea robotics, inspection and intervention, and defense-adjacent engineering work that becomes more valuable as Western governments and operators prioritize undersea infrastructure security. With share…
Cipher Mining (CIFR) just put in a high-volume breakout day, and the fundamental backdrop stays constructive: the market is rewarding miners that can credibly pivot into AI/HPC hosting and large-scale data center development. With a 3.4 GW development pipeline and multiple headlines pointing to long-duration hosting agreements, CIFR has the kind of…
Mastercard (MA) has pulled back to roughly $522 after a sharp slide from the $600s, leaving the stock oversold (RSI ~29.9) and well below its 20- and 50-day averages. With earnings due 01/29/2026 and consumer spending described as holding firm in recent coverage, MA sets up as a tactical long: defined risk below recent lows and upside toward the fi…
GLDD is trading near $15.21 with bullish momentum, improving earnings power, and strong backlog visibility. With the stock sitting above key moving averages and just below its 52-week high, this looks like a clean mid-term breakout setup where fundamentals and technicals actually agree. The trade: look for a pullback entry near support, target a re…
JFrog has re-established a credible growth narrative with recent results showing mid-20% revenue growth and outsized cloud strength, and the stock is coiling just under key moving averages after a major 2025 breakout. With a clean balance sheet (no debt-to-equity) and improving momentum signals, FROG offers a mid-term long trade setup into potentia…
Relay Therapeutics is catching a bid as optimism builds around zovegalisib (RLY-2608). With shares back near the top of the 52-week range and short interest still heavy, the next move likely comes down to whether price can hold above key moving averages and push through recent resistance. Here’s a defined long trade with a tight invalidation level …
Quest Diagnostics (DGX) is holding above key moving averages with improving momentum while fundamentals still look like what you want in a defensive compounder: scale, sticky physician relationships, and meaningful free cash flow. With MACD in bullish momentum, RSI in the mid-50s, and price consolidating below the 52-week high, the setup supports a…
Carlisle has pulled back from its highs and is now trading around $346, close to its 20-day trend and well above the 50-day. Fundamentals still look solid on cash generation and profitability, but the tape is not fully cooperative with MACD showing bearish momentum. This sets up a defined-risk long trade: buy near current levels, risk to a clean te…
Dave (DAVE) has the fundamentals of a maturing fintech, but the stock is trading like the market is bracing for higher delinquencies. With RSI near oversold and momentum still bearish, I’m looking for a failed bounce to short into, targeting a move back toward spring support levels. Trade plan: mid-term (45 trading days) short with a defined stop a…
AMD is breaking higher with bullish momentum and a valuation that’s clearly pricing in continued data center wins. The trade hinges on AMD sustaining its uptrend into the 52-week high zone while the market keeps rewarding AI infrastructure exposure. EPYC strength is the underappreciated pillar here: even if GPU headlines fluctuate, server CPU share…
Pagaya has the feel of a classic asymmetric trade: a volatile AI-fintech name that already proved it can surprise to the upside, now pulling back with momentum washed out. With PGY around $21 and sitting below key moving averages, the setup is a defined-risk bounce toward the low-to-mid $20s, with a higher-octane extension if sentiment flips. The t…
Duos Technologies is a small-cap name straddling rail automation and a fast-emerging edge data center platform. The stock is acting well, fundamentals are moving in the right direction, and short interest is non-trivial. Here’s an actionable mid-term trade plan with clear levels, plus what could derail the thesis.
Roche is pushing into obesity with CT-388 after a strong Phase 2 update, and the stock is breaking to fresh 52-week highs. The trade idea is to buy the pullback or controlled breakout, targeting a move into the low $60s while using a tight stop below trend support. The setup leans on bullish momentum, expanding attention on CT-388, and a market tha…
Seritage Growth Properties (SRG) trades like a liquidation vehicle with heavy short interest and thin liquidity. With the market focusing on past control/valuation headlines, incremental positives like term-loan debt reduction after the Aventura sale can matter disproportionately. Technically SRG is sitting below key moving averages with RSI in the…
MercadoLibre has pushed back toward the top of its 52-week range as momentum turns bullish, yet the stock still screens reasonably priced for a business with entrenched e-commerce scale and a fast-growing fintech ecosystem. With strong technicals, manageable short interest, and valuation metrics that aren’t stretched relative to quality, MELI offer…
Avita Medical (RCEL) is attempting a turnaround after a steep drawdown into early January. The stock has reclaimed key moving averages with bullish MACD momentum, while short interest remains elevated with roughly two weeks of days-to-cover. Recent symposium data added constructive narrative support around RECELL outcomes and health economics. This…
IonQ has turned into a headline-driven quantum proxy, and the latest wave of “national priority” framing around quantum plus IonQ’s aggressive M&A push is keeping buyers engaged even as the chart has cooled off. With the stock sitting below key moving averages, RSI in the low-40s, and short interest still elevated, the risk-reward favors a defined …
Rekor Systems is trading near $1.25 with an oversold tape (RSI ~29) and bearish momentum, yet the fundamental story is not standing still: Q3 2025 revenue hit a record $14.2M (+35% YoY) and the company highlighted a $50M Georgia DOT contract. With short interest still elevated and the stock far below its $3.42 52-week high, the setup favors a defin…
Pure Cycle has quietly stacked profitable quarters and just printed a sharp revenue step-up, while the stock grinds higher with bullish momentum signals. With a clean balance sheet and a business model tied to long-duration Colorado development, PCYO offers a tradable breakout/retest setup near $12 with a tight stop and a defined catalyst window.
Geron has spent the last year getting punished for a messier-than-hoped commercial ramp, and the stock price shows it. But at roughly a $0.88B market cap and ~$1.39/share, the setup is starting to look asymmetrical: the company is actively cutting costs (12/11/2025 restructuring), liquidity ratios are strong (current ~5.93, quick ~4.85), and short …
Toll Brothers has pulled back from fresh 52-week highs even as profitability and balance-sheet metrics remain solid for a cyclical builder. With TOL trading around $143 and roughly 10x earnings, the market is already pricing in a softer housing backdrop. This trade idea looks for a mid-term rebound toward the prior high while defining risk below re…
